Related references
Note: Only part of the references are listed.Low-dose decitabine priming endows CAR T cells with enhanced and persistent antitumour potential via epigenetic reprogramming
Yao Wang et al.
NATURE COMMUNICATIONS (2021)
Shaping Functional Avidity of CAR T Cells: Affinity, Avidity, and Antigen Density That Regulate Response
Raanan Greenman et al.
MOLECULAR CANCER THERAPEUTICS (2021)
T cell circuits that sense antigen density with an ultrasensitive threshold
Rogelio A. Hernandez-Lopez et al.
SCIENCE (2021)
CD70-specific CAR T cells have potent activity against acute myeloid leukemia without HSC toxicity
Tim Sauer et al.
BLOOD (2021)
Safety and feasibility of anti-CD19 CAR T cells with fully human binding domains in patients with B-cell lymphoma
Jennifer N. Brudno et al.
NATURE MEDICINE (2020)
Impaired Death Receptor Signaling in Leukemia Causes Antigen-Independent Resistance by Inducing CAR T-cell Dysfunction
Nathan Singh et al.
CANCER DISCOVERY (2020)
Tuning the Antigen Density Requirement for CAR T-cell Activity
Robbie G. Majzner et al.
CANCER DISCOVERY (2020)
KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma
Michael Wang et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
A rational mouse model to detect on-target, off-tumor CAR T cell toxicity
Mauro Castellarin et al.
JCI INSIGHT (2020)
A Distinct Transcriptional Program in Human CAR T Cells Bearing the 4-1BB Signaling Domain Revealed by scRNA-Seq
Angela C. Boroughs et al.
MOLECULAR THERAPY (2020)
Targeting CD70 with cusatuzumab eliminates acute myeloid leukemia stem cells in patients treated with hypomethylating agents
Carsten Riether et al.
NATURE MEDICINE (2020)
Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study
Jeremy S. Abramson et al.
LANCET (2020)
Loss of TET2 Uncouples Proliferative and Effector Functions in CAR T Cells
Nayan Jain et al.
BLOOD (2020)
Defining an Optimal Dual-Targeted CAR T-cell Therapy Approach Simultaneously Targeting BCMA and GPRC5D to Prevent BCMA Escape-Driven Relapse in Multiple Myeloma
Carlos Fernandez de Larrea et al.
BLOOD CANCER DISCOVERY (2020)
Hypomethylating agent alters the immune microenvironment in acute myeloid leukaemia (AML) and enhances the immunogenicity of a dendritic cell/AML vaccine
Myrna R. Nahas et al.
BRITISH JOURNAL OF HAEMATOLOGY (2019)
CAR T cell trogocytosis and cooperative killing regulate tumour antigen escape
Mohamad Hamieh et al.
NATURE (2019)
Modulation of Target Antigen Density Improves CAR T-cell Functionality and Persistence
Sneha Ramakrishna et al.
CLINICAL CANCER RESEARCH (2019)
γ-Secretase inhibition increases efficacy of BCMA-specific chimeric antigen receptor T cells in multiple myeloma
Margot J. Pont et al.
BLOOD (2019)
Screening a Broad Range of Solid and Haematological Tumour Types for CD70 Expression Using a Uniform IHC Methodology as Potential Patient Stratification Method
Tal Flieswasser et al.
CANCERS (2019)
Single Chain Variable Fragment Linker Length Regulates CAR Biology and T Cell Efficacyf
Nathan Singh et al.
BLOOD (2019)
Multiomics of azacitidine-treated AML cells reveals variable and convergent targets that remodel the cell-surface proteome
Kevin K. Leung et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2019)
c-Jun overexpression in CAR T cells induces exhaustion resistance
Rachel C. Lynn et al.
NATURE (2019)
Two-Dimensional Regulation of CAR-T Cell Therapy with Orthogonal Switches
Mylinh T. Duong et al.
MOLECULAR THERAPY-ONCOLYTICS (2019)
CD19 and CD70 Dual-Target Chimeric Antigen Receptor T-Cell Therapy for the Treatment of Relapsed and Refractory Primary Central Nervous System Diffuse Large B-Cell Lymphoma
Sanfang Tu et al.
FRONTIERS IN ONCOLOGY (2019)
Rational design of a trimeric APRIL-based CAR-binding domain enables efficient targeting of multiple myeloma
Andrea Schmidts et al.
BLOOD ADVANCES (2019)
Up-regulation of EMT-related gene VCAN by NPM1 mutant-driven TGF-beta/cPML signalling promotes leukemia cell invasion
Liyuan Yang et al.
JOURNAL OF CANCER (2019)
CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy
Terry J. Fry et al.
NATURE MEDICINE (2018)
CD70, a novel target of CAR T-cell therapy for gliomas
Linchun Jin et al.
NEURO-ONCOLOGY (2018)
Genetic Inactivation of CD33 in Hematopoietic Stem Cells to Enable CAR T Cell Immunotherapy for Acute Myeloid Leukemia
Miriam Y. Kim et al.
CELL (2018)
CAR T-cells targeting FLT3 have potent activity against FLT3(-)ITD(+) AML and act synergistically with the FLT3-inhibitor crenolanib
Hardikkumar Jetani et al.
LEUKEMIA (2018)
Compound CAR T-cells as a double-pronged approach for treating acute myeloid leukemia
Jessica C. Petrov et al.
LEUKEMIA (2018)
Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia
Joseph A. Fraietta et al.
NATURE MEDICINE (2018)
CD70 as a target for chimeric antigen receptor T cells in head and neck squamous cell carcinoma
Yuk Pheel Park et al.
ORAL ONCOLOGY (2018)
Structural principles of tumor necrosis factor superfamily signaling
Eva S. Vanamee et al.
SCIENCE SIGNALING (2018)
CARs versus BiTEs: A Comparison between T Cell-Redirection Strategies for Cancer Treatment
Clare Y. Slaney et al.
CANCER DISCOVERY (2018)
Hypoxia-inducible factor-2 alpha up-regulates CD70 under hypoxia and enhances anchorage-independent growth and aggressiveness in cancer cells
Shojiro Kitajima et al.
Oncotarget (2018)
Structural principles of tumor necrosis factor superfamily signaling
Eva S. Vanamee et al.
SCIENCE SIGNALING (2018)
Disruption of TET2 promotes the therapeutic efficacy of CD19-targeted T cells
Joseph A. Fraietta et al.
NATURE (2018)
Argx-110 Targeting CD70, in Combination with Azacitidine, Shows Favorable Safety Profile and Promising Anti-Leukemia Activity in Newly Diagnosed AML Patients in an Ongoing Phase 1/2 Clinical Trial
Adrian F. Ochsenbein et al.
BLOOD (2018)
Anti-CD37 chimeric antigen receptor T cells are active against B- and T-cell lymphomas
Irene Scarfo et al.
BLOOD (2018)
Preclinical Evaluation of Chimeric Antigen Receptors Targeting CD70-Expressing Cancers
Qiong J. Wang et al.
CLINICAL CANCER RESEARCH (2017)
CD70/CD27 signaling promotes blast stemness and is a viable therapeutic target in acute myeloid leukemia
Carsten Riether et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2017)
Function of Novel Anti-CD19 Chimeric Antigen Receptors with Human Variable Regions Is Affected by Hinge and Transmembrane Domains
Leah Alabanza et al.
MOLECULAR THERAPY (2017)
Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection
Justin Eyquem et al.
NATURE (2017)
Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas
Stephen J. Schuster et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
S. S. Neelapu et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Crystal structure of CD27 in complex with a neutralizing noncompeting antibody
Alexey Teplyakov et al.
ACTA CRYSTALLOGRAPHICA SECTION F-STRUCTURAL BIOLOGY COMMUNICATIONS (2017)
Matrix metalloproteinases - From the cleavage data to the prediction tools and beyond
Piotr Cieplak et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH (2017)
Integrating Proteomics and Transcriptomics for Systematic Combinatorial Chimeric Antigen Receptor Therapy of AML
Fabiana Perna et al.
CANCER CELL (2017)
Construction of a linker library with widely controllable flexibility for fusion protein design
Gang Li et al.
APPLIED MICROBIOLOGY AND BIOTECHNOLOGY (2016)
The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice
Elizabeth C. Townsend et al.
CANCER CELL (2016)
DNMT3A mutation leads to leukemic extramedullary infiltration mediated by TWIST1
Jie Xu et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2016)
CD123-Engager T Cells as a Novel Immunotherapeutic for Acute Myeloid Leukemia
Challice L. Bonifant et al.
MOLECULAR THERAPY (2016)
Optimized sgRNA design to maximize activity and minimize off-target effects of CRISPR-Cas9
John G. Doench et al.
NATURE BIOTECHNOLOGY (2016)
Affinity-Tuned ErbB2 or EGFR Chimeric Antigen Receptor T Cells Exhibit an Increased Therapeutic Index against Tumors in Mice
Xiaojun Liu et al.
CANCER RESEARCH (2015)
pVHL/HIF-Regulated CD70 Expression Is Associated with Infiltration of CD27+ Lymphocytes and Increased Serum Levels of Soluble CD27 in Clear Cell Renal Cell Carcinoma
Melanie Ruf et al.
CLINICAL CANCER RESEARCH (2015)
T cells compete by cleaving cell surface CD27 and blocking access to CD70-bearing APCs
Matthew A. Burchill et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2015)
Treatment of CD33-directed Chimeric Antigen Receptor-modified T Cells in One Patient With Relapsed and Refractory Acute Myeloid Leukemia
Quan-shun Wang et al.
MOLECULAR THERAPY (2015)
4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors
Adrienne H. Long et al.
NATURE MEDICINE (2015)
The Phyre2 web portal for protein modeling, prediction and analysis
Lawrence A. Kelley et al.
NATURE PROTOCOLS (2015)
Acute Myeloid Leukemia
Hartmut Doehner et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Identification of Chimeric Antigen Receptors That Mediate Constitutive or Inducible Proliferation of T Cells
Matthew J. Frigault et al.
CANCER IMMUNOLOGY RESEARCH (2015)
How I treat the older patient with acute myeloid leukemia
Gert Ossenkoppele et al.
BLOOD (2015)
T cells expressing CD123-specific chimeric antigen receptors exhibit specific cytolytic effector functions and antitumor effects against human acute myeloid leukemia
Armen Mardiros et al.
BLOOD (2013)
The Tumor Necrosis Factor Receptor Stalk Regions Define Responsiveness to Soluble versus Membrane-Bound Ligand
Christine Richter et al.
MOLECULAR AND CELLULAR BIOLOGY (2012)
Fiji: an open-source platform for biological-image analysis
Johannes Schindelin et al.
NATURE METHODS (2012)
T cells redirected against CD70 for the immunotherapy of CD70-positive malignancies
Donald R. Shaffer et al.
BLOOD (2011)
Matrix Metalloproteinase-8 Is Overexpressed in Waldenstrom's Macroglobulinemia Cells, and Specific Inhibition of this Metalloproteinase Blocks Release of Soluble CD27
Yangsheng Zhou et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2011)
SPICE: Exploration and Analysis of Post-Cytometric Complex Multivariate Datasets
Mario Roederer et al.
CYTOMETRY PART A (2011)
Kit inhibitor APcK110 extends survival in an AML xenograft mouse model
Stefan Faderl et al.
INVESTIGATIONAL NEW DRUGS (2011)
Timing and tuning of CD27-CD70 interactions: the impact of signal strength in setting the balance between adaptive responses and immunopathology
Martijn A. Nolte et al.
IMMUNOLOGICAL REVIEWS (2009)
Trimer Stabilization, Oligomerization, and Antibody-Mediated Cell Surface Immobilization Improve the Activity of Soluble Trimers of CD27L, CD40L, 41BBL, and Glucocorticoid-Induced TNF Receptor Ligand
Agnes Wyzgol et al.
JOURNAL OF IMMUNOLOGY (2009)
Metalloprotease inhibitors block release of soluble CD27 and enhance the immune stimulatory activity of chronic lymphocytic leukemia cells
Kazunori Kato et al.
EXPERIMENTAL HEMATOLOGY (2007)
Share Paper
